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ABSTRACT: The main objective of the present work is to perform molecular docking studies of the ligand 2-
Mercapto-5-(3-Methoxy phenyl) 1,3,4 oxadiazole with protein focal adhesion kinase. A good correlation was 
observed in binding affinity of this complex. Using different inhibitors for this enzyme, it can be used as an 
anticancer therapy target. 
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INTRODUCTION 
Oxadiazole is a five membered heterocyclic aromatic compound [1]. Out of its four possible isomers 1,3,4-
oxadiazole is widely exploited for various applications. These are azoles with oxygen and nitrogen.1,3,4-oxadiazole 
exhibit wide range of biological activities like, antibacterial, fungicidal, anti-inflammatory, analgesic, antipyretic, 
anti-tubercular, sedative and hypnotics, hypoglycemic agents, light screening agents, dyes and x-ray contrast 
materials[2,3]. The lead compound has been synthesized by incorporating substituents at 2nd and 5th  position of the 
1,3,4-oxadiazole heterocyclic ring system. It is clear from various literatures that these derivatives possess 
remarkable inhibitor for cancer activity [4,5]. The molecular docking studies of 2-Mercapto-5-(3-Methoxyphenyl) 
with protein focal adhesion kinase (FAK) was performed by using Argus lab.Docking studies have become nearly 
indispensable for study of macromolecular structures and interactions. Macromolecular modeling by docking studies 
provides most detailed possible view of drug receptor interaction and has created a new rational approach to drug 
design. Here the structure of drug is designed, based on its fit to three dimensional structures of receptor site, rather 
than by analogy to other active structures. 
MATERIALS AND METHODS 
Database and Software 
Data collection and cell refinement- CAD-4 software, Data reduction- MOLEN, Structure solution and refinement - 
SHELXL97, Molecular graphics-ORTEP and PLATON, Manuscript preparation for publication -SHELX97, 
program used for docking Aurgus lab and Pymol, File Format conversion of the coordinates- openbabel. 
Preparation of ligand structure  
The crystals of the compound2-Mercapto-5-(3-methoxyphenyl) 1, 3, 4-oxadiazole [6,7] were grown by slow 
evaporation technique using ethanol as solvent. The x-ray intensity data of the crystals were collected on a Bruker 
smart CCD diffractometer on graphite monochromatic Mokα radiation. Crystal data are given in the Table 1 and 
chem3D structure of ligand is shown Figure 1. 
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Table 1:  Crystal data of 2-Mercapto-5-(3-methoxyphenyl) 1, 3, 4-oxadiazole 
Identification code GBD-1 
Empirical formula C9 H8 N2 O2 S 
Formula weight 208.23 
Temperature 293(2) K 
Wavelength 0.71073 Å 
Crystal system orthorhombic 
Space group Pn21a 
Unit cell dimensions 
a=9.4447(18) Å  α=900 
b=6.7023(13) Å  β=900 
c=15.260 (3) Å   γ=900 
Volume 966.0(3) A^3 
Z 4 
Calculated density 1.432Mg/m3 
Absorption 
coefficient 0.308mm^-1 
F (000) 432 
Crystal size 0.4x0.35x0.3mm 
Theta range for data 
collection 2.54 to 27.96 deg 
Limiting indices -12<=h<=11,-8<=k<=8, -19<=1<=20 
Reflections collected 
/ unique 7720/2223 [R(int)=0.0212] 
Completeness to 
theta 98.2% 
Absorption 
correction none 
Refinement method Full matrix least  squares on F^2 
Data / restraints / 
parameters 2223/1/148 
Goodness-of-fit on 
F^2 1.102 
Final R indices 
[I>2sigma(I)] R1=0.0544, wR2=0.1335 
R indices (all data) R1=0.0692 wR2=0.1437 
Absolute structure 
parameter 0.8(2) 
Extinction 
coefficient 0.0018 (16) 
Largest diff. peak 
and hole 0.446 and -0.202 e A^-3 
 
Figure 1: Structure of 2-Mercapto-5-(3-Methoxyphenyl) 1,3,4 oxadiazole 
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Preparation of protein structure 
The 3D structure of FAK (PDB code: 2ETM) [8] was downloaded from protein data bank. The protein showed 
anticancer activity from the literature [9].The Pdb file was converted to ent file, all water molecules were removed 
and hydrogen atoms are added to the protein by using argus software. 
Protein ligand interaction using Argus lab 4.0.1 
Argus lab is an electronic structure program that is based on the quantum mechanics. It predicts the potential 
energies, molecular structures, geometry optimization of structure, and vibrational frequencies of coordinates of 
atoms, bond lengths, and bond angles. FAK was docked against the 2-Mercapto-5-(3-methoxyphenyl) 1, 3, 4-
oxadiazole compound using argus lab 4.0.1 [10]. The interaction was carried out to find the favorable binding 
geometries of the ligand with the protein. Docking of the protein ligand complex was mainly targeted to the 
predicted active site. Docking was performed by selecting Argus dock as the docking engine. The selected residues 
of the receptor were defined to be part of the binding site. A spacing of 0.4 Ǻ between the grid points was used and 
an exhaustive search was performed by enabling high precision option. Dock was chosen as the calculation type, 
flexible for the ligand and the score was used as the scoring function. A maximum of 150 posses were allowed to be 
analyzed, binding site box size was set to 39x39x39 Ǻ so as to encompass the entire active site.  The score function 
with the parameters read from the score. The entire compound in the data set was docked into the active site of FAK 
protein, using the same protocol. The docking poses saved for the compound were ranked according to their dock 
score function. The pose having the highest dock score was selected for further analysis. The ligand was docked with 
the target protein, and the best docking poses were identified. 
 
RESULT AND DISCUSSION 
The designed series of 1, 3, 4-oxadiazole were docked to the FAK protein with argus lab software. Docking result 
shows the best 9 binding sites (Table 2). Docked energy of 6.84913 Kcal/mol with two hydrogen bond shown in 
Figure 2. There was a change in the ligand structure after binding to the receptor shown in Figure 3. The molecular 
docking studies resulted in highlighting the ligands and their conformations which efficiently fit into the cavity of 
target protein. The higher the negative value of the energy of binding the better is affinity of the molecule to the 
receptor. Analysis of these ligands with the proteins brought in focus some important interactions operating at the 
molecular level.  
Table 2: Best docking pose energy 
Pose 
fitness 
Affinity  
Kcal/mol 
0 -6.84913 
1 -6.77539 
2 -6.77382 
3 -6.77382 
4 -6.77217 
5 -6.76806 
6 - 6.76806 
7 -6.76734 
8 -6.7654 
9 -6.75904 
 
Figure 2: Binding pose of 1, 3,4oxadiazole in binding site 
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Figure 3: Changes in Ligand structure after Binding to receptor 
 
CONCLUSION 
The ligand synthesized for this study is considered as orally safe compound. The intermolecular interactions between 
the ligand and the protein were investigated. Synthesized chemical compound showed good fit with the protein.Thus 
the bioactive compound interacting with the target can be used as a potent inhibitor to block the action of FAK 
protein. The selected ligand can be verified at wet laboratory validations and made into an effective anticancer drug. 
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